Ganglioside GD2 in reception and transduction of cell death signal in tumor cells

BMC Cancer

Roman V Kholodenko²  Irina M Molotkovskaya²  Dmitry Y Ryazantsev²  Eugene D Ponomarev¹  Irina V Kholodenko³  Polina A Vishnyakova²  Igor I Doronin² 

[1]School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin NT, Hong Kong, China

[2]Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya St., 16/10, Moscow 117997, Russia

[3]Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, 10, Pogodinskaya St., Moscow 119121, Russia

关键词: Tumor-associated gangliosides;    Cell death;    Cytotoxicity;    Anti-GD2 mAbs;    GD2;   

Others  :  858862
DOI  :  10.1186/1471-2407-14-295

 received in 2013-11-17, accepted in 2014-04-22,  发布年份 2014

【 摘 要 】

Background

Ganglioside GD2 is expressed on plasma membranes of various types of malignant cells. One of the most promising approaches for cancer immunotherapy is the treatment with monoclonal antibodies recognizing tumor-associated markers such as ganglioside GD2. It is considered that major mechanisms of anticancer activity of anti-GD2 antibodies are complement-dependent cytotoxicity and/or antibody-mediated cellular cytotoxicity. At the same time, several studies suggested that anti-GD2 antibodies are capable of direct induction of cell death of number of tumor cell lines, but it has not been investigated in details. In this study we investigated the functional role of ganglioside GD2 in the induction of cell death of multiple tumor cell lines by using GD2-specific monoclonal antibodies.

Methods

Expression of GD2 on different tumor cell lines was analyzed by flow cytometry using anti-GD2 antibodies. By using HPTLC followed by densitometric analysis we measured the amount of ganglioside GD2 in total ganglioside fractions isolated from tumor cell lines. An MTT assay was performed to assess viability of GD2-positive and -negative tumor cell lines treated with anti-GD2 mAbs. Cross-reactivity of anti-GD2 mAbs with other gangliosides or other surface molecules was investigated by ELISA and flow cytometry. Inhibition of GD2 expression was achieved by using of inhibitor for ganglioside synthesis PDMP and/or siRNA for GM2/GD2 and GD3 synthases.

Results

Anti-GD2 mAbs effectively induced non-classical cell death that combined features of both apoptosis and necrosis in GD2-positive tumor cells and did not affect GD2-negative tumors. Anti-GD2 mAbs directly induced cell death, which included alteration of mitochondrial membrane potential, induction of apoptotic volume decrease and cell membrane permeability. This cytotoxic effect was mediated exclusively by specific binding of anti-GD2 antibodies with ganglioside GD2 but not with other molecules. Moreover, the level of GD2 expression correlated with susceptibility of tumor cell lines to cytotoxic effect of anti-GD2 antibodies.

Conclusions

Results of this study demonstrate that anti-GD2 antibodies not only passively bind to the surface of tumor cells but also directly induce rapid cell death after the incubation with GD2-positive tumor cells. These results suggest a new role of GD2 as a receptor that actively transduces death signal in malignant cells.

【 授权许可】

   
2014 Doronin et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Svennerholm L, Boström K, Fredman P, Jungbjer B, Lekman A, Mansson JE, Rynmark BM: Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994, 1214:115-123.
• [2]Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984, 44:5914-5920.
• [3]Wu ZL, Schwartz E, Seeger R, Ladisch S: Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986, 46:440-443.
• [4]Tsuchida T, Saxton RE, Morton DL, Irie RF: Gangliosides of human melanoma. J Natl Cancer Inst 1987, 78:45-54.
• [5]Chang HR, Cordon-Cardo C, Houghton AN, Cheung NK, Brennan MF: Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 1992, 70:633-638.
• [6]Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, Cheung NK: Localization of GD2-specific monoclonal antibody 3 F8 in human osteosarcoma. Cancer Res 1987, 47:5377-5381.
• [7]Navid F, Santana VM, Barfield RC: Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 2010, 10:200-209.
• [8]Alvarez-Rueda N, Leprieur S, Clémenceau B, Supiot S, Sébille-Rivain V, Faivre-Chauvet A, Davodeau F, Paris F, Barbet J, Aubry J, Birklé S: Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin Cancer Res 2007, 13:5613-5620.
• [9]Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K: An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res 2002, 93:816-824.
• [10]Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H: The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett 2009, 281:171-182.
• [11]Kholodenko RV: Apoptosis-inducing activity of monoclonal antibodies 14G2a to tumor-associated ganglioside GD2 in T-cell lymphoma EL-4. Sovremennye problemy venerologii, immunologii i vrachebnoy kosmetologii. (Russia) 2010, 8:17-23.
• [12]Doronin II, Kholodenko IV, Molotkovskaya IM, Kholodenko RV: Preparation of Fab-fragments of GD2-specific antibodies and analysis of their antitumor activity in vitro. Bull Exp Biol Med 2013, 154:658-663.
• [13]Folch J, Lees M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
• [14]Ledeen RW, Yu RK: Gangliosides: structure, isolation, and analysis. Methods Enzymol 1982, 83:139-191.
• [15]Telford WG, King LE, Fraker PJ: Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods 1994, 172:1-16.
• [16]Kholodenko R, Kholodenko I, Sorokin V, Tolmazova A, Sazonova O, Buzdin A: Anti-apoptotic effect of retinoic acid on retinal progenitor cells mediated by a protein kinase A-dependent mechanism. Cell Res 2007, 17:151-162.
• [17]Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
• [18]Kholodenko RV, Sapozhnikov AM, Mikhalev II, Molotkovsky JG, Molotkovskaya IM: Caspase participation in the apoptosis induced in the CTLL-2 cell line by gangliosides. Membr Cell Biol 2002, 19:209-215.
• [19]Molotkovskaya IM, Kholodenko RV, Zelenova NA, Sapozhnikov AM, Mikhalev II, Molotkovsky JG: Gangliosides induce cell apoptosis in the cytotoxic line CTLL-2, but not in the promyelocyte leukemia cell line HL-60. Membr Cell Biol 2000, 13:811-822.
• [20]Kozber D: Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens. Immunologic Res 2010, 46:23-31.
• [21]Magnani JL: Carbohydrate differentiation and cancer-associated antigens detected by monoclonal antibodies. Biochem Soc Trans 1984, 12:543-545.
• [22]Patel K, Rossell RJ, Pemberton LF, Cheung NK, Walsh FS, Moore SE, Sugimoto T, Kemshead JT: Monoclonal antibody 3 F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2. Br J Cancer 1989, 60:861-866.
• [23]Nakamura K, Hanibuchi M, Yano S, Tanaka Y, Fujino I, Inoue M, Takezawa T, Shitara K, Sone S, Hanai N: Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody. Cancer Res 1999, 59:5323-5330.
• [24]Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Pérez R: Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008, 7:2033-2041.
• [25]Cochonneau D, Terme M, Michaud A, Dorvillius M, Gautier N, Frikeche J, Alvarez-Rueda N, Bougras G, Aubry J, Paris F, Birklé S: Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo. Cancer Lett 2013, 333:194-204.
• [26]Kholodenko IV, Doronin II, Vishnyakova PA, Bolkhovitina EL, Molotkovskaya IM, Kholodenko RV: Antitumor activity of GD2-specific antibodies and their Fab-fragments in the mouse tumor model. Immunologiya (Russia) 2013, 34:199-203.
• [27]Holmgren J, Lonnroth I, Mansson J, Svennerholm L: Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci 1975, 72:2520-2524.
• [28]Swaminathan S, Eswaramoorthy S: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000, 7:693-699.
• [29]Montecucco C: How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 1986, 11:314-317.
• [30]Maria D, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R: Requirement for GD3 ganglioside in CD95- and ceramide induced apoptosis. Science 1997, 277:1652-1655.
• [31]Molotkovskaya IM, Kholodenko RV, Molotkovsky JG: Influence of gangliosides on the IL-2- and IL-4-dependent cell proliferation. Neurochem Res 2002, 27:761-770.
• [32]Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K: Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 1986, 102:688-696.
• [33]Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY: Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012, 1:477-486.
• [34]Agrawal V, Frankel AE: 14G2a anti-GD2 crossreactivity with the CD166 antigen. J Immunother 2010, 33:1014-1015.
• [35]Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K: Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 2001, 61:4244-4252.
• [36]Hernández AM, Rodríguez N, González JE, Reyes E, Rondón T, Griñán T, Macías A, Alfonso S, Vázquez AM, Pérez R: Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011, 186:3735-3744.
• [37]Vishnyakova PA, Doronin II, Kholodenko IV, Ryazantsev DY, Molotkovskaya IM, Kholodenko RV: Caspases participation in the cell death, induced by GD2-specific monoclonal antibody. Bioorg Khim 2014, 40:1-10.
• [38]Sorice M, Matarrese P, Tinari A, Giammarioli AM, Garofalo T, Manganelli V, Ciarlo L, Gambardella L, Maccari G, Botta M, Misasi R, Malorni W: Raft component GD3 associates with tubulin following CD95/Fas ligation. FASEB J. 2009, 23:3298-3308.